https://doi.org/10.55788/1d8314a3
FSHD is caused by the misexpression of the double homeobox protein 4 (DUX4) transcription factor in skeletal muscle. This condition ultimately results in progressive motor disability. Currently, no treatment options are available for FSHD that prevent or slow muscle weakness and wasting. Losmapimod is an orally active, selective, small molecule inhibitor of p38α/β that reduced DUX4. It has been evaluated in over 3,500 subjects in clinical trials across 10 other indications, with no safety signals. The efficacy and safety results of losmapimod from the phase 2 ReDUX4 trial were presented by Prof. Al-Rabi N. Tawil (University of Rochester, NY, USA) [1]. Enrolled were 80 FSHD participants aged 18–65 years (mean age 46 years) who were randomised 1:1 to losmapimod (15 mg twice daily) or matching placebo.
Losmapimod exhibited expected pharmacokinetic and target engagement in blood and muscle. No difference was observed in DUX4-driven gene expression in muscle biopsy, which was the study's primary endpoint (26.16 for losmapimod vs 25.68 for placebo; difference 0.43; 95% CI -1.04–1.89; P=0.56). At week 48, losmapimod did demonstrate significantly better muscle health. Muscle fat infiltration (MFI) was 0.03% versus 0.52% (difference -0.49; 95% CI -0.86 to -0.12; P=0.01). Significant improvements were also measured in Reachable Workspace (RWS) with weights, Patients' Global Impression of Change (PGIC), and dynamometry. There was a non-significant slowing of progression in Timed Up and Go (TUG) completion, and no differences in FSHD-TUG, motor function measurement (MFM), or FSHD-Health Index.
Losmapimod was well tolerated with no serious drug-related adverse events (AEs). Treatment-emergent AEs occurred in 29 (73%) and 23 (58%) patients in the experimental and placebo group, respectively. In both groups, most treatment-emergent AEs were mild or moderate and deemed unrelated to study drug. A phase 3 trial is in preparation.
- Tawil R, et al. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in Subjects with FSHD: ReDUX4. S23.007, AAN 2022, 02–07 April, Seattle, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« SRP-9001 for treating patients with Duchenne muscular dystrophy Next Article
Gene therapy effective in older patients with spinal muscular atrophy »
« SRP-9001 for treating patients with Duchenne muscular dystrophy Next Article
Gene therapy effective in older patients with spinal muscular atrophy »
Table of Contents: AAN 2022
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer’s Disease and Other Dementias
Targeting senescent cells to treat age-related diseases
Cardiorespiratory fitness protects against dementia
Safety and effects of bosutinib in Lewy body dementia
Epilepsy
“Women with epilepsy should be encouraged to breastfeed”
Fenfluramine: possible new treatment for Lennox-Gastaut syndrome
Laser interstitial thermal therapy for refractory epilepsy
Migraine
Migraine may be an important obstetric risk factor
Intranasal zavegepant safe and well tolerated in healthy adults
Telemedicine during COVID-19 pandemic highly appreciated
Multiple Sclerosis
Ublituximab versus teriflunomide in relapsing MS patients
Ketogenic diet may improve disability and quality of life
Favourable additional safety data for ofatumumab
Predicting new T2 lesions using a machine learning algorithm
Evobrutinib reduces volume of slowly expanding lesions
Sustained long-term efficacy and safety of satralizumab in NMOSD
Muscle and Neuro-Muscular Disorders
Ravulizumab in patients with generalised myasthenia gravis
Gene therapy effective in older patients with spinal muscular atrophy
Losmapimod for facioscapulohumeral muscular dystrophy
SRP-9001 for treating patients with Duchenne muscular dystrophy
Cerebrovascular Disease and Stroke
Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out?
Better outcomes with mechanical thrombectomy in elderly stroke patients
Plasma NfL levels associated with cardiovascular risk
Non-invasive vagus nerve stimulation for acute stroke
Parkinson’s Disease
Prasinezumab in Parkinson’s disease: delayed-start analysis of PASADENA trial
IPX203 versus immediate release carbidopa-levodopa
Impact of COVID-19 public health interventions
COVID-19
Cognitive, EEG, and MRI features in COVID-19 survivors
Neurological manifestations of COVID-19 worsen prognosis
New evidence for biological basis of “COVID-19 brain fog”
Related Articles
June 16, 2021
The neurological impact of COVID-19
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com